FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/27/2025
Back to search
Official data from USPTO
CELLIXIR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
48
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5
Filing date
03/12/2021
Registration date
12/24/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/24/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
FR
Examiner
COUGHLAN, REBECCA D.
Law office
M40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CELLECTIS
Representatives
Mary Margaret L. O'Donnell Blue Filament Law PLLC
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals and biochemical products for industrial and scientific use and not for medical or veterinary usefor transferring biological molecules into living cells and for integrating foreign nucleic acids into the genome of living cells; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposesfor the transfer of chemical or biological molecules into living cells and the integration of foreign nucleic acids into the genome of living cells; biological preparations for laboratory useother than for medical and veterinary use; diagnostic preparationsother than for medical and veterinary use; peptide substratesprotein arrays and nucleic acids or complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexes for clinical or medical laboratory usefor identifying genetic expression and protein location and integration of foreign nucleic acids into the genome of living cells; chemical and biochemical preparations for industrial and scientific use; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposesfor cellular and gene engineering and analysis in laboratories; Chemicalsstandard solutions and buffers used in analytical chemistry for transferring chemical and biological molecules into living cellsintegration of foreign nucleic acids into the genome of living cells and transient production of proteins or nucleic acids; aqueous chemical and biochemical solutions containing nutrients for cultivating living cells for use in electroporation; biological cell and tissue cultures for laboratory use other than for medical and veterinary use; diagnostic reagents other than for medical and veterinary use; peptide substratesprotein array and nucleic acids or complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for clinical or medical laboratory usein particular for detecting and monitoringfor integrating foreign nucleic acids into the genome of living cells and transient production of proteins; transfection reagents in the nature of chemical and biochemical reagentsused for transient production of proteinsother than for medical and veterinary use
Class 5
Pharmaceutical and veterinary preparationscellstissuesgrafts engineering reagent for medical or veterinary purposes; diagnostic preparations for medical and veterinary use; living cells and cultures of microorganisms as well as protein arrayssynthetic peptides for the treatment of bloodgeneticimmune disorders and cancer and nucleic acid sequences and complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for medical and veterinary use; living cells and cultures of microorganisms as well as proteins arrayssynthetic peptides and nucleic acids sequences and complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for medical and clinical use for the treatment of genetic defects in gene therapyviral and infectious diseasescardiovascular diseases and cancer; diagnostic preparations for medical and veterinary usein particular for the diagnosis and analysis of genetic defectsviral and infectious diseasescardiovascular diseases and cancer; living cellscultures of microorganismsproteins arrayssynthetic peptides and nucleic acids sequences and complexes of these moleculesribo-nucleo and desoxyribo-nucleo complexesnucleo-proteo complexes for medical and veterinary usein particular for medical and clinical use for the treatment of genetic defects in gene therapyviral and infectious diseasescardiovascular diseases and cancer
Publications
History of USPTO decisions and trademark events.
48 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/10/2025
FIMP
FINAL DISPOSITION PROCESSED
06/09/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/24/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/24/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/24/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/05/2024
PUBO
PUBLISHED FOR OPPOSITION
11/05/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/16/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/30/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
09/30/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/30/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
09/30/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/30/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/09/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/04/2024
GNFR
FINAL REFUSAL E-MAILED
04/04/2024
CNFR
FINAL REFUSAL WRITTEN
04/04/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
02/14/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/18/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
08/10/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
01/26/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/27/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/07/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/07/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/12/2022
GNSL
LETTER OF SUSPENSION E-MAILED
06/12/2022
CNSL
SUSPENSION LETTER WRITTEN
06/12/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/26/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/25/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/25/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/25/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/25/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/25/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/25/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/25/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/25/2022
RFNT
REFUSAL PROCESSED BY IB
11/23/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/29/2021
RFRR
REFUSAL PROCESSED BY MPU
10/29/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/28/2021
CNRT
NON-FINAL ACTION WRITTEN
10/27/2021
DOCK
ASSIGNED TO EXAMINER
10/12/2021
MAFR
APPLICATION FILING RECEIPT MAILED
07/10/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/01/2021
Continuous trademark protection
Get notified about every new filing that threatens CELLIXIR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.